Sign in

What researchers published on Follicular lymphoma

3,593 papers, newest first.

Showing 20 of 350

  • Trial resultCD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.The Lancet. Haematology
  • Trial resultEpcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial.The Lancet. Haematology
  • Trial resultGlofitamab in combination with immunochemotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Phase 1b dose-escalation study.British journal of haematology
  • Trial resultExposure-Response Analyses to Inform the Optimal Epcoritamab Monotherapy Dosing Regimen in Relapsed or Refractory Follicular Lymphoma.Clinical pharmacokinetics
  • Trial resultA distinct CAR-T cell phenotype mediates therapeutic response at limited doses.Nature communications
  • Trial resultDurable efficacy and manageable long-term safety of lisocabtagene maraleucel for 3L+ FL: 3-year update from TRANSCEND FL.Blood
  • Trial resultMRD negativity by PBMCs and ctDNA confirms deep and durable responses after epcoritamab monotherapy in R/R FL.Blood advances
  • Trial resultComparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma.Oncoimmunology
  • Trial resultPhase I study of glofitamab in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma.International journal of clinical oncology
  • Randomised trialRENOIR phase 3 rituximab-lenalidomide vs rituximab as maintenance treatment in relapsed/refractory follicular lymphoma.Blood advances
  • Randomised trialTen-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.The New England journal of medicine
  • Trial resultAbexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 study.Signal transduction and targeted therapy
  • Randomised trialLenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Randomised trialLenalidomide-rituximab or lenalidomide-rituximabbendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL study.Haematologica
  • Trial resultCheckpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naïve follicular lymphoma: Results from the phase II 'FLUORO' study.British journal of haematology
  • Trial resultComparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: growth modulation index analysis from the ROSEWOOD study.ESMO open
  • Randomised trialLenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.Blood
  • Trial resultFixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.American journal of hematology
  • Trial resultCost-Effectiveness Analysis of PI3K Inhibitors for Relapsed or Refractory Follicular Lymphoma in China: A Comparison Between Linperlisib and Duvelisib.Clinical drug investigation
  • Randomised trialTreatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial.JAMA oncology